Rigel Pharmaceuticals, Incorporated

Tarikere Gururaja

Rajinder Paul Singh

Taisei Kinoshita

Hui Li

Donald G Payan

Esteban Masuda

Kin Tso

Stephanie Yung

Rongxian Ding

Ankush Argade

David Carroll

David C Anderson

Methods for treating an inflammatory disorder and for inhibiting the production of IL-23 using 2,4-pyrimidinediamine compounds represented by formula (I): 

Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds

2,4-Pyrimidinediamine compounds represented by formula (I), methods for preparing the same and methods for treating an inflammatory disorder and for inhibiting the production of IL-23 and/or stimulating the production of IL-10 using the same: 

2,4-pyrimidinediamine compounds for treatment of inflammatory disorders

The present disclosure provides 4-pyrimidineamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.

4-pyrimidineamine compounds and their uses as anti-proliferative agents

The present invention is directed to compositions and methods including peptides which have a high affinity for each other and, when linked to a protein, are used to help fold the protein into a compact structure. By virtue of its stability and constraints, this scaffold can prolong the activity of any embedded protein sequences in the presence of cellular and other proteases. The compact structure can have other functional sequences embedded, and is preferable to linear and less constrained peptides for library screening, for creating structurally-biased peptide libraries and for targeting to specific intracellular and extracellular compartments. Compositions of the present invention can be displayed on the surface of viruses, archaebacteria, prokaryotic and eukaryotic cells for library screening, drug screening and display. Methods of the present invention are useful for screening in vivo for intracellular effector proteins modulating signaling pathways and to identify interacting proteins in vitro. Thus, the present invention is useful as a scaffold for gene therapy, for the isolation of new therapeutic drug leads and for potential use as a therapeutic in physiological fluids.

Peptides causing formation of compact structures

Growing community of inventors

Santa Clara, CA, United States of America

Tarikere Gururaja